BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

NCT02326844 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Study was closed by the Cancer Therapy Evaluation Program (CTEP)

Conditions

Ovarian Cancer

Interventions

DRUG: BMN 673 (talazoparib)

Sponsor

National Cancer Institute (NCI)